Clinical trials
Squamous Cell Carcinoma clinical trials
Below are recruiting squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 882 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06050707RecruitingPhase 2
MRI-guided radiation therapy for anal cancer
This trial tests a new, more precise type of radiation therapy for anal cancer. It uses daily MRI scans to adjust the radiation dose based on how the tumor shrinks, aiming to give stronger treatment to the cancer while protecting healthy tissue.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06081673RecruitingPhase 2
Penpulimab plus chemo before and after surgery for head and neck cancer
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06085781Recruiting
MRI and tumor study for head and neck cancer patients
This trial uses special MRI scans to look at your head, neck, and tumor environment before treatment. It aims to find better ways to understand your cancer and guide care.
Toronto, OntarioAges 18 years+ - NCT06087614RecruitingPhase 2
Higher-dose radiation for head and neck cancer
This trial tests a higher dose of radiation therapy that is adjusted based on oxygen levels in the tumor. It may help people with certain head and neck cancers that have not been treated before.
DelhiAges 18–70 - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06130332RecruitingPhase 2
Immunotherapy Plus Chemo Before Surgery for Early Oral Cancer
This trial tests a new immunotherapy drug (tirellizumab) combined with chemotherapy before surgery for early-stage oral cancer. It aims to see if this combination can help shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06137274RecruitingPhase 2
Adaptive radiation boost for head and neck cancer
This trial tests a new way of giving radiation therapy, called adaptive radiation boost, for people with head and neck cancer. The goal is to see if this approach can better target the cancer and possibly improve outcomes.
Tampa, FloridaAges 18 years+ - NCT06138028RecruitingPhase 2/Phase 3
Sintilimab plus chemo and radiation for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Qingdao, ShandongAges 18–80 - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06173986RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for advanced esophageal cancer
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
ShanghaiAges 18–75 - NCT06186609RecruitingPhase 2
PD-1 Inhibitor and Radiation for Elderly Esophageal Cancer
This trial tests whether combining a PD-1 inhibitor (a type of immunotherapy) with radiation therapy can help older adults (70+) with esophageal squamous cell cancer who cannot have surgery. The goal is to see if this treatment is safe and effective for those with limited options.
Nantong, JiangsuAges 70 years+ - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+ - NCT06190782RecruitingPhase 3
Local therapy for limited metastatic esophageal cancer
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
ShanghaiAges 18 years+ - NCT06194734RecruitingPhase 3
KC1036 vs. chemo for advanced esophageal cancer
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
BeijingAges 18–75 - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06248996RecruitingPhase 3
Testing a stronger radiation schedule for large head and neck cancers
This trial tests whether giving a slightly different schedule of radiation (more frequent, smaller doses) can improve treatment for people with large head and neck cancers. It is for patients who are getting radiation as their main treatment, sometimes with chemotherapy as well.
GävleAges 18–100 - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Jonesboro, ArkansasAges 18 years+ - NCT06272214RecruitingPhase 2
Adjuvant radiotherapy for esophageal cancer after immunotherapy
This trial tests if adding radiation therapy after surgery improves outcomes for people with esophageal squamous cell cancer who received immunotherapy and chemotherapy before surgery but did not achieve a complete response. It aims to see if this approach can lower the chance of the cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT06304350RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06321003Recruiting
Testing AI to detect early oral cancer with light scans
This trial uses a special light-based scanner (OCT) and artificial intelligence to help diagnose early signs of mouth cancer or precancer. It aims to see if this combination can make diagnosis easier and more accurate.
PalermoAges 18–99 - NCT06336941Recruiting
Ultrasound of the tongue for oral cancer
This study is testing a new way to take pictures of the tongue using a special ultrasound probe that goes inside the mouth. The goal is to see how well this method can show tumor details before surgery.
PisaAges 18 years+ - NCT06353685RecruitingPhase 2
Less radiation after surgery for oral cancer with good response
This trial is testing whether giving less radiation after surgery is safe and effective for people with oral cancer whose surgery results were very good (no cancer cells or very few left). It aims to reduce side effects while still preventing cancer from coming back.
GuangzhouAges 18–80
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell carcinoma?
- Yes. Clin2 currently lists 882 recruiting squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.